Merck ’s Keytruda receives accelerated FDA approval for GEJ adenocarcinoma

Merck ’s Keytruda (pembrolizumab) has received approval from the US Food and Drug Administration (FDA) to treat patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news